
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class...
- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to...
- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron®...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.48 | 3.99334442596 | 12.02 | 15 | 10.51 | 453847 | 13.18486643 | CS |
4 | 10.12 | 425.210084034 | 2.38 | 21.78 | 1.87 | 3109154 | 9.41346362 | CS |
12 | 9.43 | 307.166123779 | 3.07 | 21.78 | 1.62 | 996875 | 9.16608986 | CS |
26 | 8.95 | 252.112676056 | 3.55 | 21.78 | 1.62 | 717269 | 8.87720679 | CS |
52 | 8.95 | 252.112676056 | 3.55 | 21.78 | 1.62 | 717269 | 8.87720679 | CS |
156 | 8.95 | 252.112676056 | 3.55 | 21.78 | 1.62 | 717269 | 8.87720679 | CS |
260 | 8.95 | 252.112676056 | 3.55 | 21.78 | 1.62 | 717269 | 8.87720679 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions